Rhode Island 2026 Regular Session

Rhode Island House Bill H7075

Introduced
1/14/26  

Caption

RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES --, THE MATTHEW FEDERICO DIABETIC SAFETY ACT

Impact

The bill seeks to enhance the health and safety of individuals with diabetes by making critical treatment options more accessible. By eliminating copayments and deductibles for glucagon, it addresses a significant barrier that often prevents timely administration of this life-saving medication. Additionally, it provides clarity on health plan responsibilities regarding coverage, thus establishing a more supportive framework for diabetes management within the community.

Summary

House Bill 7075, known as the Matthew Federico Diabetic Safety Act, mandates that all health insurance contracts providing prescription coverage in Rhode Island must include at least one type of glucagon auto-injector or nasal spray without requiring a copayment or deductible. This provision aims to improve access to essential diabetes treatment by ensuring that individuals experiencing hypoglycemia can obtain the necessary medical intervention without financial barriers. The requirement will take effect on January 1, 2027, allowing time for insurance companies to adapt their policies accordingly.

Contention

While proponents of the bill argue that it will save lives by increasing access to glucagon during emergencies, there are concerns about the financial implications for health insurers and the potential for increased premium costs. Critics may point to the need for careful monitoring of the market impacts following the implementation of this requirement, raising questions about long-term sustainability and affordability in the state’s health insurance landscape. Nonetheless, the bill has garnered support from various sugar advocacy groups and diabetes organizations advocating for improved health outcomes.

Companion Bills

No companion bills found.

Previously Filed As

RI H5173

Requires health plans that provide prescription benefits to cover at least one type of glucagon auto-injector, nasal spray, or formulation that does not require reconstitution to treat hypoglycemia. No copayment or deductible would be required.

RI S0115

Requires health plans that provide prescription benefits to cover at least one type of glucagon auto-injector, nasal spray, or formulation that does not require reconstitution to treat hypoglycemia. No copayment or deductible would be required.

RI S0649

Provides for the sale and regulation of pet insurance policies and their contents and provisions.

RI H5499

Seeks to promote increased consumer access to Medicare supplement health insurance policies.

RI S0267

Seeks to promote increased consumer access to Medicare supplement health insurance policies.

RI S0103

Mandates all insurance contracts, plans or policies provide insurance coverage for the expense of diagnosing and treating infertility, for women between the ages of 25 and 42 years including preimplantation genetic diagnosis (PGD) in conjunction with IVF.

RI H5627

Requires health insurance providers to provide insurance coverage for pharmacists’ services.

RI S0897

Requires health insurance providers to provide insurance coverage for pharmacists’ services.

RI H6032

Requires at fault insurance companies to provide to any claimant whose vehicle is damaged in an accident, to provide a vehicle that is comparable to the claimant’s vehicle and that rental charges shall be based on local retail prices.

RI S0925

Requires at fault insurance companies to provide to any claimant whose vehicle is damaged in an accident, to provide a vehicle that is comparable to the claimant’s vehicle and that rental charges shall be based on local retail prices.

Similar Bills

FL H0597

Diabetes Management in Schools

NJ A4548

Concerns administration of ready-to-use undesignated glucagon rescue therapy in public schools.

WV SB92

Glucagon for Schools Act

FL S0772

Diabetes Management in Schools

KY HB75

AN ACT relating to undesignated glucagon.

KY HB174

AN ACT relating to undesignated glucagon.

FL HB597

Diabetes Management in Schools:

KY HB263

AN ACT relating to undesignated glucagon.